Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CVS Caremark

The Drug Pricing Machine and Why Patients Keep Paying More

Roughly a third of American adults report difficulty paying for prescription drugs, and many are forced to skip doses, delay refills, or abandon treatment altogether.

International Business Times

ARS Pharmaceuticals Q1 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy, its needle-free epinephrine treatment for allergic reactions including anaphylaxis. Co-founder

MarketBeat

Forced to sell medications at a loss, rural Texas pharmacies seek new survival tactics

Independent rural pharmacists are starting other businesses or selling baby shower gifts to keep their stores operating. Pharmacy deserts affect 4 million Texans.

The Texas Tribune

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Medication Timing Rules That Affect Coverage

In 2026, getting your medication covered isn’t just about having a valid prescription—it’s about timing. With the rollout of the new $2,100 out-of-pocket cap for...

Saving Advice

CVS under investigation for sending text messages to customers lobbying against proposed bill

A Louisiana bill that died in the Senate would have prevented CVS from operating in the state as a pharmacy while also owning pharmacy benefit managers

The Independent UK

What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices for everyone

Wegovy and Ozempic are weight loss drugs that promise to transform the treatment of obesity, heart disease and other chronic conditions that afflict millions of Americans. But while everyone agrees these drugs have the potential to transform lives, no one can agree on how best to pay for them.

The Conversation

The pharmacy benefit management sector just might be set for a VC-backed shakeup, says Rightway CEO and cofounder Jordan Feldman

In 2023, about 80% of all prescription drug claims in the U.S. were processed by only three companies. VC-backed Rightway CEO and cofounder Jordan Feldman says there’s an opportunity for disruption.

Fortune

Read news from The Economist, FT, and more,
with one subscription

‘Insane’ limits on anti-nausea pills hit cancer patients and doctors

The conflict shows how poor communication can complicate even simple acts of care in the fragmented US health care system

The Independent UK

James Comer gives major pharmacy benefit managers hard deadline to change 'materially false' statements

Comer claims statements about them not steering patients to PBM-owned pharmacies are false and reminds witnesses that lying under oath can send them to prison

Latin Times

Mark Cuban’s $141K mistake: The Cost Plus Drugs cofounder says CEOs don’t understand health care coverage, and it’s costing them big

The billionaire entrepreneur spoke to Fortune after participating in a White House roundtable discussion on bringing transparency to the role of prescription drug middlemen.

Fortune

Mark Cuban’s Cost Plus Drugs will begin manufacturing its own medications this week

The "Shark Tank" investor and Cost Plus Drugs cofounder Dr. Alex Oshmyansky participated in a White House health care roundtable.

Fortune

Have a complaint about CVS? So do pharmacists: Many just walked out

After a large walkout forced at least a dozen stores to shut down in the Kansas City area, CVS promises change. But critics say the crisis in staffing and unfair pay extends beyond that market.

WEKU

3 Hot Stocks Under $10 for Your September Watchlist

These outperformers are all trading under $10 per share - for now. After beating the S&P 500 year-to-date, analysts think these standout single-digit stocks all have room to keep running higher.

Barchart

Drug company middlemen likely to be a focus in 118th Congress

WASHINGTON — Factions of the health care system and members of Congress are turning their fire on an oft-maligned part of the drug pricing system — the middlemen who negotiate discounts with drug companies on behalf of health plans.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Roll Call

Drug company middlemen likely to be a focus in 118th Congress - Roll Call

PBMs argue that the rebates they collect from drug companies in exchange for coverage by a health plan are used to lower premiums.

Tribune News Service

Federal regulators probe Cigna’s pharmacy benefit manager, CVS Caremark, and others. What are they investigating?

Express Scripts, the pharmacy benefit manager that Cigna Corp. bought in 2018, is being investigated by the Federal Trade Commission for what regulators claim is influence over drug prices wielded by pharmacy benefit managers and transparent business practices.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Federal Trade Commission

190 stories

Cigna

128 stories

Ohio State University

Senate Finance Committee

49 stories

Travelzoo

46 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.